Filtered By:
Condition: Bleeding
Countries: Japan Health
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 236 results found since Jan 2013.
Different Determinants of the Recurrence of Atrial Fibrillation and Adverse Clinical Events in the Mid-Term Period After Atrial Fibrillation Ablation
CONCLUSIONS: This study disclosed different determinants of post-ablation recurrence and AEs. Female sex, persistent AF, and enlarged LAd were determinants of post-ablation recurrence, whereas an old age, comorbidities, and LV and renal dysfunction rather than post-ablation recurrence were AEs determinants. These findings will help determine ablation indications and post-ablation management.PMID:34219078 | DOI:10.1253/circj.CJ-21-0326
Source: Circulation Journal - July 5, 2021 Category: Cardiology Authors: Ryuta Watanabe Koichi Nagashima Yuji Wakamatsu Naoto Otsuka Katsuaki Yokoyama Naoya Matsumoto Takayuki Otsuka Shinya Suzuki Akio Hirata Masato Murakami Mitsuru Takami Masaomi Kimura Hidehira Fukaya Shiro Nakahara Takeshi Kato Hiroshi Hayashi Yu-Ki Iwasaki Source Type: research
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Aortic dissection diagnosed on stroke computed tomography protocol: a case report
ConclusionsWhen acute stroke is suspected due to neurological deficits, plain head CT is the first choice for imaging diagnosis. The addition of cervical CT angiography can reliably exclude stroke due to aortic dissection. CTP can identify ischemic penumbra, which cannot be diagnosed by plain head CT or diffusion-weighted magnetic resonance imaging. These combined stroke CT protocols helped us avoid missing an aortic dissection.
Source: Journal of Medical Case Reports - May 26, 2021 Category: General Medicine Source Type: research
Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study
CONCLUSION: In contemporary PCI practice, nearly half of patients had HBR and presence of HBR significantly increased risk of ischemic/thrombotic events. Both aspirin and P2Y12 inhibitor monotherapy following short DAPT had low and comparable ischemic/bleeding events.PMID:33875313 | DOI:10.1016/j.jjcc.2021.03.015
Source: Journal of Cardiology - April 20, 2021 Category: Cardiology Authors: Hirofumi Hioki Ken Kozuma Yoshihisa Kinoshita Mamoru Nanasato Yoshiaki Ito Junichi Yamaguchi Nobuo Shiode Kiyoshi Hibi Kengo Tanabe Junya Ako Yoshihiro Morino Atsushi Hirohata Shinjo Sonoda Yoshihisa Nakagawa Hisayuki Okada Takuo Nakagami Itaru Takamisawa Source Type: research
Association of Low Body Weight with Clinical Outcomes in Elderly Atrial Fibrillation Patients Receiving Apixaban —J-ELD AF Registry Subanalysis
ConclusionsThe incidence of events in each body weight group was comparable for stroke or systemic embolism and bleeding requiring hospitalization, and body weight<50 kg might not be an independent risk for death in Japanese non-valvular AF patients aged ≥ 75 years taking on-label doses of apixaban.
Source: Cardiovascular Drugs and Therapy - April 8, 2021 Category: Cardiology Source Type: research
Effectiveness and Safety of Rivaroxaban by General Practitioners - A Multicenter, Prospective Study in Japanese Patients With Non-Valvular Atrial Fibrillation (GENERAL)
CONCLUSIONS: The low incidence of adverse events, including stroke/SE and bleeding, in patients prescribed rivaroxaban by general practitioners supports its use as a safe and efficacious treatment in the standard clinical care of high-risk patient populations.PMID:33814525 | DOI:10.1253/circj.CJ-20-1244
Source: Circulation Journal - April 5, 2021 Category: Cardiology Authors: Kengo Kusano Nobuyoshi Sugishita Masaharu Akao Hikari Tsuji Kunihiko Matsui Shinya Hiramitsu Yutaka Hatori Hironori Odakura Hiroyuki Kamada Koji Miyamoto Hisao Ogawa Source Type: research
Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study
We examined 6806 patients whose baseline CrCl data were available and classified them into 2 groups: normal renal function group with CrCl ≥ 50 mL/min (n = 5326, 78%) and renal dysfunction group with CrCl < 50 mL/min (n = 1480, 22%). In the normal renal function group, 1609 (30%) received 10 mg/day (under-dose), while in the renal dysfunction group, 108 (7%) received 15 mg/day (over-dose). In the normal renal function group, under-dose of rivaroxaban was associated with higher all-cause mortality, while in t he renal dysfunction group, over-dose was associated with higher incidence of major bleed...
Source: Heart and Vessels - March 16, 2021 Category: Cardiology Source Type: research
Impact of Frailty on Bleeding Events Related to Anticoagulation Therapy in Patients With Atrial Fibrillation.
CONCLUSIONS: Frailty is associated with increased bleeding events related to anticoagulant therapy in patients previously hospitalized with AF. Greater care should be taken with patients with a CHS frailty index ≥2.
PMID: 33504742 [PubMed - as supplied by publisher]
Source: Circulation Journal - January 27, 2021 Category: Cardiology Authors: Ohta M, Hayashi K, Mori Y, Sato H, Noto T, Kawahatsu K, Mita T, Kazuno Y, Sasaki S, Doi T, Hirokami M, Tanaka S, Yuda S Tags: Circ J Source Type: research
Clinical outcomes according to dose reduction criteria of apixaban in Japanese elderly patients with atrial fibrillation: J-ELD AF Registry subanalysis
AbstractDose reduction of apixaban is applied in atrial fibrillation (AF) patients fulfilling ≥ 2 of the following criteria: (1) age ≥ 80 years, (2) body weight ≤ 60 kg and (3) serum creatinine ≥ 1.5 mg/dL. However, the clinical significance of each criterion remains unclear. The J-ELD AF Registry is a prospective observational study of elderly (≥ 75 years) J apanese AF patients receiving on-label dose of apixaban. In patients receiving the standard dose (5 mg bid,n = 1243), the incidence rates (% per patient-year) of stroke or systemic embolism in those fulfilling none [n = 516] o...
Source: Heart and Vessels - January 24, 2021 Category: Cardiology Source Type: research
